Evidence map›Paper›PMID 38243928›Full record

ArticleRecent patents on anti-cancer drug discovery2025

Curcumin Inhibits the Growth of Hepatocellular Carcinoma

Jiaqi Su, Xianbing Liu, Xiaoyue Zhao, Hongjie Ma, Yuzhu Jiang, Xu Wang, Peiyuan Wang, Mingdong Zhao, Xuemei Hu

Open access · hybridAbstract read
PubMed Publisher
In one paragraph

Article in Recent patents on anti-cancer drug discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Jiaqi SuDepartment of Imaging, Binzhou Medical University, Yantai, 264003, Shandong, China.
Xianbing LiuDepartment of Immunology, Binzhou Medical University, Yantai, 264003, Shandong, China.
Xiaoyue ZhaoDepartment of Clinical Psychology, Yantai Affiliated Hospital of Binzhou Medial University, Yantai, 264100, Shandong, China.
Hongjie MaDepartment of Immunology, Binzhou Medical University, Yantai, 264003, Shandong, China.
Yuzhu JiangDepartment of Immunology, Binzhou Medical University, Yantai, 264003, Shandong, China.
Xu WangDepartment of Imaging, Binzhou Medical University, Yantai, 264003, Shandong, China.
Peiyuan WangDepartment of Imaging, Binzhou Medical University, Yantai, 264003, Shandong, China.
Mingdong ZhaoDepartment of Imaging, Binzhou Medical University, Yantai, 264003, Shandong, China.
Xuemei HuDepartment of Immunology, Binzhou Medical University, Yantai, 264003, Shandong, China.ORCID 0000-0003-3584-5639
Binzhou Medical University · CNBinzhou University · CN

Funding

Natural Science Foundation of Shandong Province, China ZR2018MH034Taishan Scholar Foundation of Shandong province ts201712066
6 · The paper itself

Abstract

backgroundCurcumin has been reported to have anti-hepatocellular carcinoma (HCC) effects, but the underlying mechanism is not well known.

objectivesTo investigate whether membrane-associated RING-CH 1 (MARCH1) is involved in the curcumin-induced growth suppression in HCC and its underlying molecular mechanism. A few recent patents for curcumin for cancer are also reviewed in this article.

methodsThe effect of curcumin on growth inhibition of HCC cells was analyzed through in vitro and in vivo experiments, and the expression levels of MARCH1, Bcl-2, VEGF, cyclin B1, cyclin D1, and JAK2/STAT3 signaling molecules were measured in HCC cells and the xenograft tumors in nude mice. Cell transfection with MARCH1 siRNAs or expression plasmid was used to explore the role of MARCH1 in the curcumin-induced growth inhibition of HCC cells.

resultsCurcumin inhibited cell proliferation, promoted apoptosis, and arrested the cell cycle at the G2/M phase in HCC cells with the decrease of Bcl-2, VEGF, cyclin B1, and cyclin D1 expression as well as JAK2 and STAT3 phosphorylation, resulting in the growth suppression of HCC cells. MARCH1 is highly expressed in HCC cells, and its expression was downregulated after curcumin treatment in a dose-dependent manner. The knockdown of MARCH1 by siRNA decreased the phosphorylation levels of JAK2 and STAT3 and inhibited the growth of HCC cells. In contrast, opposite results were observed when HCC cells overexpressed MARCH1. A xenograft tumor model in nude mice also showed that curcumin downregulated MARCH1 expression and decelerated the growth of transplanted HCC with the downregulation of JAK2/STAT3 signaling and functional molecules. The ADC value of MRI analysis showed that curcumin slowed down the progression of HCC.

conclusionOur results demonstrated that curcumin may inhibit the activation of JAK2/STAT3 signaling pathway by downregulating MARCH1 expression, resulting in the growth suppression of HCC. MARCH1 may be a novel target of curcumin in HCC treatment.

Indexed as

Antineoplastic AgentsCarcinoma, HepatocellularCurcuminJanus Kinase 2Liver NeoplasmsSTAT3 Transcription FactorAnimalsApoptosisCell Line, TumorCell ProliferationHumansMiceMice, Inbred BALB CMice, NudeSignal TransductionXenograft Model Antitumor AssaysAntineoplastic AgentsCurcuminJAK2 protein, humanJanus Kinase 2STAT3 protein, humanSTAT3 Transcription Factoranti-tumor activitycurcuminHepatocellular carcinomaJAK2MARCH1STAT3.

Identifiers

PMID38243928
OpenAlexW4391067271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.